A new report authored by a team at the Yale Cancer Center presents a synopsis of lung cancer treatments over the past 20 years. According to co-lead author Dr. Roy Herbst, chief of medical oncology at Yale Cancer Center, "options for treatments have improved in recent years with the advent of two classes of drugs - molecularly targeted therapies, and more recently, immunotherapies."
To read more about this report, click here.
No comments:
Post a Comment